Nasdaq · Pharmaceutical Preparations
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $271.0M | −$186.6M | −$176.1M | — | 60,845,550 |
| FY2021 | $351.4M | −$454.0M | −$411.8M | — | 67,795,540 |
| FY2022 | $363.3M | −$707.4M | −$496.6M | — | 69,914,225 |
| FY2023 | $434.2M | −$606.6M | −$519.1M | — | 73,543,862 |
| FY2024 | $560.2M | −$569.2M | −$421.7M | — | 90,538,118 |
| FY2025 | $673.0M | −$575.0M | −$472.0M | — | 98,600,000 |
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Ultragenyx Pharmaceutical Inc. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
